Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Aptiv Solutions ADDPLAN® DF is the First Validated Software to Use MCP-Mod Methodology

Published: Thursday, October 31, 2013
Last Updated: Thursday, October 31, 2013
Bookmark and Share
MCP-Mod methodology was recently qualified by EMA for reducing bias and error in dose finding clinical trials.

Aptiv Solutions announce that the European Medicines Agency (EMA) has issued a qualification opinion finding that the MCP-Mod1 methodology for dose finding provides the potential to “enable more informative Phase II study designs” and “provide a more solid basis for all subsequent dose selection strategies and decisions”. MCP-Mod is a core component of Aptiv Solutions ADDPLAN® DF software, currently the only validated commercial software available for this methodology.

Estimating dose-response and selecting the appropriate dose for Phase III trials is one of the most difficult challenges of the drug development process, according to the EMA. Currently half of Phase III trials fail, in part because of sub-optimal and inefficient practices for dose selection in Phase II. Current approaches for estimating the target dose are also prone to uncertainty, which can result in the use of an inappropriate statistical model that over- or under-estimates the true effective dose.

“Regulatory agencies and drug developers are concerned with safety and tolerability if the dose is too high and inadequate efficacy if the dose is too low. Accurately defining this risk/benefit ratio is critical to the clinical development process, both to ensure patient safety and the successful approval of groundbreaking medications,” says Professor Andy Grieve, Senior Vice President, Clinical Trial Methodology for Aptiv Solutions.

The MCP-Mod approach is unique in that it defines several plausible candidate dose-response models, tests them for significance, and then identifies the most appropriate statistical approach to model dose-response and estimate the target dose. 

In the extensive simulations reviewed for the qualification opinion, the EMA found that the MCP-Mod methodology appears to be better than the common pairwise ANOVA-based approach in terms of bias and absolute error. “ANOVA approaches work well if the true dose response model is linear, but many drugs do not behave this way,” says Grieve. For other common dose-response relationships, such as a non-linear Emax scenario, the EMA found the ANOVA approach is always among the worst methods to estimate dose response. The EMA also identified that MCP-Mod controls the Type 1 error rate and is less likely than a pairwise ANOVA-based approach to identify a clinically relevant dose in the absence of true dose-response.

“This is a significant shift for the industry. The EMA opinion challenges the way most dose finding studies are performed, essentially saying that the number of doses and the dose range selected are sub-optimal. This leads to poor selection of the effective dose at Phase II, which causes significant problems in subsequent clinical trials,” says Grieve. 

ADDPLAN® DF is a fully-validated design and analysis tool based on MCP-Mod and covers dose finding designs for establishing Proof of Concept and determining the optimum target dose to select for Phase III trials.

In July, ADDPLAN® DF was pre-released in beta version to a top 10 pharma company that served as the prime development partner for the software. The fully validated version launched in September. Two additional top 10 pharma customers are now using the software as founding members of the ADDPLAN® DF Consortium announced earlier this year. 

This release of ADDPLAN® DF is the first in a series of novel methodologies from Aptiv Solutions for use in Phase II clinical trials. 

The white paper titled ‘ADDPLAN® DF - An Advanced Tool for Optimizing Dose Selection in Exploratory Drug Development’ is available below:


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Aptiv Solutions to be Acquired by ICON
Combined companies provide unrivalled capabilities for adaptive and medical device trials worldwide.
Monday, March 31, 2014
Tufts CSDD Study Finds Adoption of Adaptive Clinical Trial Designs is Increasing
Report shows growing acceptance by pharmaceutical companies and regulatory agencies.
Friday, May 24, 2013
Aptiv Solutions Growing: Opens New Office in North Carolina
New office is located at 4505 Emperor Boulevard in the Imperial Center.
Monday, December 10, 2012
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Computerized Flexible Needles Prove Themselves in Biological Tissue
The advantage of the system is that you can avoid obstacles with the needles or critical tissues and that the system during the insertion of the needle in real time can adjust the path if, for example, the tissue deforms.
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Overdose of Vitamin D in Teenagers May Lead to Increased Cholesterol Levels
Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.
Phase 2 Trials Underway for New Single Dose Malaria Treatment
The new drug, which prevents the malaria parasite from reproducing and spreading, is now undergoing Phase II clinical trials in humans.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!